PM
INO icon

Pembroke Management’s Inovio Pharmaceuticals INO Stock Holding History

Pembroke Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,083
Closed -$52K – 65
2018
Q4 		$52K Buy
+1,083
New +$65.8K 0.01% 56

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pembroke Management's INO Position: Q1 2019 in Review

Pembroke Management sold out of Inovio Pharmaceuticals (INO) in Q1 2019, closing a stake of 1,083 shares — an estimated $52K sold.

Pembroke Management first reported a position in INO in Q4 2018 and held it in 1 quarter. The position peaked at $52K in Q4 2018. 127 funds tracked by Wall St. Rank hold INO as of Q1 2019.

  • Pembroke Management reported no remaining Inovio Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Pembroke Management sold 1,083 Inovio Pharmaceuticals shares in Q1 2019, an estimated $52K.
  • Pembroke Management first reported a position in Inovio Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Pembroke Management's Inovio Pharmaceuticals position peaked at $52K in Q4 2018.
  • 127 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2019.

Based on Pembroke Management's 13F filing for Q1 2019, filed 12 Apr 2019.